<DOC>
	<DOCNO>NCT00003038</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy suramin plus doxorubicin treating patient advance solid tumor .</brief_summary>
	<brief_title>Combination Chemotherapy With Suramin Plus Doxorubicin Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) suramin follow doxorubicin patient advance solid tumor . II . Describe toxic effect suramin sequential dos doxorubicin patient . III . Assess development peripheral neuropathy patient treatment . IV . Assess preliminary evidence antitumor effect regimen patient . VI . Explore relationship pharmacokinetic parameter potential neurotoxicity suramin patient . OUTLINE : This dose-escalation study doxorubicin . Patients receive suramin IV daily 1-2 hour day 1-4 follow doxorubicin IV 10-15 minute day 5 . Treatment repeat every 4 week 3 course absence unacceptable toxicity , disease progression , clinical deterioration . Starting course 4 , patient receive alternate course doxorubicin IV day 1 every 4 week ( course 4 , 6 , 8 , etc . ) suramin doxorubicin ( course 5 , 7 , 9 etc . ) describe . Cohorts 3-6 patient receive escalate dos doxorubicin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Stable patient achieve disease response able receive target cumulative dose doxorubicin may discontinue doxorubicin receive suramin alone every 8 week . Patients follow 3 month . PROJECTED ACCRUAL : A maximum 20 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adrenocortical Carcinoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Suramin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologic cytologic confirmation malignant solid tumor include , limited : Breast cancer Prostate cancer Colon cancer Adrenocortical tumors No CNS metastases No conventional therapy cure palliation available PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : aPTT PT great upper limit normal ( ULN ) Bilirubin great 1.5 time ULN AST great 2 time ULN Albumin least 3.0 g/dL Renal : Creatinine clearance least 50 mL/min Sodium potassium normal Cardiovascular : Ejection fraction normal prior doxorubicin therapy No New York Heart Association class III IV heart disease No history significant cardiac arrhythmia No history congestive heart failure Neurologic : No seizure disorder No grade 2 great peripheral neuropathy Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No insulindependent diabetes mellitus No uncontrolled infection No chronic debilitate disease PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy immunotherapy No concurrent immunotherapy No concurrent filgrastim ( GCSF ) sargramostim ( GMCSF ) Chemotherapy : More 4 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) recover Prior doxorubicin allow total dose less 300 mg/m2 No concurrent chemotherapy No 2 prior chemotherapy regimens metastatic disease Endocrine therapy : No current steroid use great 1.5 mg dexamethasone ( equivalent ) per day Radiotherapy : At least 4 week since prior radiation therapy No radiation therapy great 25 % bone marrow No concurrent radiotherapy Surgery : At least 4 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV adrenocortical carcinoma</keyword>
	<keyword>recurrent adrenocortical carcinoma</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>